

# Ronald Witteles

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3852810/publications.pdf>

Version: 2024-02-01

34  
papers

2,691  
citations

759233

12  
h-index

434195

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

2720  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. <i>New England Journal of Medicine</i> , 2018, 379, 1007-1016.	27.0	1,558
2	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 161-172.	2.8	338
3	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. <i>Circulation: Heart Failure</i> , 2019, 12, e006075.	3.9	312
4	Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> (<scp>ATTR&ACT</scp>) and long&term extension study. <i>European Journal of Heart Failure</i> , 2021, 23, 277-285.	7.1	103
5	High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. <i>JAMA Cardiology</i> , 2022, 7, 386.	6.1	63
6	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. <i>BMC Family Practice</i> , 2020, 21, 198.	2.9	60
7	Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury. <i>JACC: CardioOncology</i> , 2021, 3, 428-440.	4.0	42
8	Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis. <i>Journal of Cardiac Failure</i> , 2019, 25, 307-311.	1.7	41
9	TNF-alpha inhibition for the treatment of cardiac sarcoidosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 546-552.	3.4	27
10	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. <i>JACC: CardioOncology</i> , 2021, 3, 537-546.	4.0	21
11	Patient Outcomes when Housestaff Exceed 80 Hours per Week. <i>American Journal of Medicine</i> , 2016, 129, 993-999.e1.	1.5	16
12	Portable Ultrasound Device Usage and Learning Outcomes Among Internal Medicine Trainees: A Parallel&Group Randomized Trial. <i>Journal of Hospital Medicine</i> , 2020, 15, 154-159.	1.4	13
13	Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry). <i>American Journal of Cardiology</i> , 2017, 120, 1381-1386.	1.6	12
14	Avoiding Catastrophe. <i>Circulation: Heart Failure</i> , 2021, 14, e008225.	3.9	9
15	A resident-created hospitalist curriculum for internal medicine housestaff. <i>Journal of Hospital Medicine</i> , 2016, 11, 646-649.	1.4	8
16	A high value care curriculum for interns: a description of curricular design, implementation and housestaff feedback. <i>Postgraduate Medical Journal</i> , 2017, 93, 725-729.	1.8	8
17	Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab. <i>Blood</i> , 2016, 128, 4525-4525.	1.4	8
18	Misconceptions and Facts About Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 2021, 160, 99-105.	1.6	7

#	ARTICLE	IF	CITATIONS
19	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009038.	3.9	6
20	Premature ventricular contractions causing pacemaker-mediated tachycardia: A failure of postventricular atrial refractory period after premature ventricular contraction extension?. <i>Heart Rhythm</i> , 2005, 2, 1389-1390.	0.7	5
21	Genomics in medicine: a novel elective rotation for internal medicine residents. <i>Postgraduate Medical Journal</i> , 2019, 95, 569-572.	1.8	5
22	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. <i>Blood</i> , 2020, 136, 44-45.	1.4	5
23	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. <i>Blood</i> , 2021, 138, 2721-2721.	1.4	5
24	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. <i>Blood</i> , 2021, 138, 2720-2720.	1.4	4
25	Ibrutinib-associated atrial fibrillation treatment with catheter ablation. <i>HeartRhythm Case Reports</i> , 2021, 7, 713-716.	0.4	4
26	Developing Therapy for Transthyretin Amyloidosis. <i>American Journal of Medicine</i> , 2022, , .	1.5	4
27	Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4610-4610.	1.6	2
28	Free Light-Chain Levels in Patients with Transthyretin Amyloid Cardiomyopathy in Attr-ACT. <i>Blood</i> , 2021, 138, 3787-3787.	1.4	2
29	Thrombophilia testing in the inpatient setting: impact of an educational intervention. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 167.	3.0	1
30	Reply to the letter regarding the article "Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (<scp>ATTR</scp>ACT</scp>) and long-term extension study"™. <i>European Journal of Heart Failure</i> , 2021, 23, 1057-1058.	7.1	1
31	Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis. <i>Blood</i> , 2016, 128, 2330-2330.	1.4	1
32	AL Amyloidosis: Prognosis of Cardiac Involvement Reconsidered.. <i>Blood</i> , 2009, 114, 4872-4872.	1.4	0
33	AL Amyloidosis and Concomitant Myeloma: Time to Reconsider Assumptions. <i>Blood</i> , 2010, 116, 4044-4044.	1.4	0
34	A Pilot Study of Melphalan, Lenalidomide and Dexamethasone In AL Amyloidosis: Interim Results. <i>Blood</i> , 2010, 116, 1946-1946.	1.4	0